How PRRT can Improve Care for Neuroendocrine Tumor Patients
Learn more about how Peptide Receptor Radionuclide Therapy (PRRT) can [...]
Real-world data analysis of efficacy and survival after Lu-177 PSMA
177Lu-PSMA radioligand therapy provides a significant response rate with a [...]
PSMA Lu-177 x Ac-225
Available since 2015, the treatment of patients with metastatic castration-resistant [...]
Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model
Joint radionuclide therapy and immunotherapy approach. The combination shows promising [...]
NET Patient Testimonial, how PRRT saved Tom’s life
Tom is a composer, pianist, audio producer and neuroendocrine tumor patient. [...]
Diagnostic accuracy of F-18-PSMA-1007-PET/CT imaging for prostate carcinoma
J. Nucl. Me. 2020 Aug 17 18F-PSMA-1007-PET/CT reliably detects malignant [...]
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients
First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T [...]
Cancer awareness month – September, don’t forget to remember
The month of September represents the prostate cancer, thyroid cancer, [...]
ProsTIC – The new Centre of Excellence
Congratulations Peter MacCallum Cancer Centre for the launch of The Prostate [...]
Prostate Cancer Theranostics – An Overview
The implementation of theranostic approaches to characterize and personalize patient [...]